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Background/aim: Degenerative disc disease (DDD) is one of the main causes of lower back pain. In this study, we evaluate the efficacy
of percutaneous intradiscal GelStix administration in patients with discogenic pain due to lumbar DDD who were unresponsive to
conservative methods.
Materials and methods: A total of 29 patients were included in the study, which took place between 2013 and 2017. Sedation was
performed in the prone position in the operating room, and a C-arm was located so as to provide a lateral view of the surgical field.
A 22-G, 3.5-inch needle was inserted into the center of the disc under fluoroscopy guidance, and a percutaneous intradiscal GelStix
implantation was performed. All patients were evaluated using the Oswestry Disability Index (ODI) and a visual analogue scale (VAS)
before and after treatment, and using the Patient Satisfaction Scale at 12 months following treatment.
Results: The mean VAS scores were 7.14 ± 0.64 at baseline and 2.48 ± 0.63 at 12 months (P < 0.001). The mean ODI scores were 28.14 ±
1.81 at baseline and 17.35 ± 0.67 at 12 months (P < 0.001). There was a statistically significant decrease in the VAS and ODI scores before
and after treatment. A total of 86.2% of the patients rated the procedure as very good or good at 12 months.
Conclusion: Our study results suggest that GelStix treatment is useful in pain relief in patients with DDD from the first month of
treatment.
Key words: Degenerative disc disease, hydrogel, GelStix

1. Introduction
Degenerative disc disease (DDD) is closely related with aging
and lumbar back pain (LBP), which affects 70%–85% of the
population during their lifetimes [1]. The prevalence of back
pain increases with aging. Approximately 20% of young
individuals have mild disc degeneration. The incidence of
degeneration increases with aging, particularly in males;
therefore, nearly 10% and 60% of discs in people aged 50
and 70 years, respectively, are severely degenerated [2].
The most important change caused by degeneration
is the loss of proteoglycans (PGs). This may lead to a
decrease in the osmotic pressure of the discal matrix and
loss of hydration [3]. Furthermore, impaired nutrient
transport in degenerated discs may lead to the formation
of lactic acid and decreased pH levels [4]. There are many
additional patient-specific factors that can contribute to the
pathogenesis of the disease, and that have the potential to
alter the natural course of disc degeneration. These include
age, sex, genetics, smoking, cardiovascular disease, morbid

obesity, physical inactivity, occupational factors (recurrent
heavy lifting and vibration), constitutional weakness, lowgrade discitis, spinal instability, and malignancy [5,6].
Hydrogels are water-soluble, and their hydrophilic
features are suitable for minimally invasive spinal surgery,
particularly surgery in which the hydrogel is transformed
into a different form after implantation. In such cases, the
minimized aqueous nature allows the implant to act as an
interspinal expander [6].
There is a need for percutaneous interventional
treatments between conservative and surgical methods
that address the etiology of DDD but cause minimal
damage to the annulus fibrosus (AF). It is difficult for the
native nucleus pulposus (NP) to achieve self-renewal;
however, hydrogels may serve as a substitute for the NP
thanks to their hydrophilic and rheological properties and
their similarities to native NP tissue.
A hydrogel agent that ideally is injectable into the
disc may improve the regeneration of NP and increase
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the mechanical function of the degenerative motional
segment, particularly in patients with early or moderate
degeneration who are unresponsive to conservative
treatments [7,8]. In the present study, we evaluate the
efficacy of percutaneous intradiscal GelStix administration
in patients with discogenic pain due to lumbar DDD who
were unresponsive to conservative methods.
2. Materials and methods
2.1. Material selection
GelStix (Replication Medical, NCT02763956) is a modified
filamentous version of polyacrylonitrile that enlarges in
volume after implantation. As with previously used in situ
hydration polymers, a number of complications have been
reported, including disintegration of the gel after swelling
[8]. Accordingly, NP-class polymers for NP implant
hydration have been used with caution [9,10]. GelStix
implants take the elongated hydrogel form of the registered
polymer of RMI and are produced as matched bone that
can be inserted under local anesthesia via 22-G needles.
GelStix Nucleus Augmentation hydrates by absorbing the
body’s own liquids, and its volume is expanded around
tenfold and is reduced in less than 15 min.
2.2. Patient selection
The inclusion criteria were as follows: being older
than 18 years of age; being within American Society of
Anesthesiologists Class I–II; having a visual analogue
scale (VAS) score of ≥5/10 points; having discogenic pain
due to 1 or 2 degenerative disc diseases; having a black
disc, as confirmed by magnetic resonance imaging (MRI)
compatible with clinical examinations; negative facet joint
blocks and medial branch blocks; and having refractory
symptoms despite physical therapy, muscle relaxant, and
antiinflammatory treatment for at least 3 months.
The exclusion criteria were as follows: patients
with root compression or zygapophyseal arthrosis as
documented by plain X-ray and lumbar MRI, and those
with vertebral fractures, previous lumbar spine surgery,
signs or symptoms of lumbar canal stenosis, psychological
disorders, localized or systemic infections, tumors,
coagulopathy, pregnancy, osteoarthritis-disc herniationannular tear (Grade >4 Modified Dallas Grading), disc
height of 5 mm or less than 50% of the original height, and
a body mass index of ≥35 kg/m2.
Of the total patients involved in the study, 8 had middle
lumbar axial pain (n = 8) and mild radiculopathy (n = 3).
2.3. The procedure
The study was approved by the Ethics Committee and
was conducted in accordance with the principles of the
Declaration of Helsinki. Written informed consent was
obtained from each patient. The data of patients who were
treated in our pain clinic with percutaneous intradiscal
GelStix implantation for LBP between 2013 and 2017 were

analyzed retrospectively, and data related to lumbar disc
degeneration, medical history, physical examination, plain
radiography, and MRI findings were recorded.
The procedures were carried out under sterile
conditions using fluoroscopy with a standard oblique
intradiscal approach. Prior to the procedure, 1 g of
intravenous cefazolin for prophylaxis and 2–5 mg of
midazolam to reduce anxiety and discomfort were
administered. The patients were thus calm but alert and
conscious, and able to talk to the practitioner to report
any unusual pain. During the procedure, blood pressure,
heart rate, electrocardiography, oxygen saturation, and
respiration rate were monitored for all patients.
The participants were placed in the prone position on
the operating table, the operational area was cleaned and
covered with sterile cloth, and an interventional point was
identified under fluoroscopy and marked 8–10 cm laterally
from the lumbar vertebrae on the side of intervention. A
local anesthetic of 60 mg of prilocaine was injected into
the subcutaneous tissues, and a 22-G, 3.5-inch needle
was inserted into the center of the disc under fluoroscopy
guidance. After entry was made, the position of the needle
within the disc was checked via both anteroposterior
and lateral views. Before installing the GelStix cartridge,
liquids were removed using a stylus. The protective cap of
the implant holder was removed and the holder was then
pushed into the proximal end of the introducer needle
and locked. It was confirmed that the tip of the needle was
located at the center of the disc cavity by fluoroscopy, and
the piston of the holder was pushed to allow the implant
to completely pass the needle, with 3 implants placed
at each disc level. Care was taken to avoid twisting the
needle. While the needle tip was still at the center of the
nucleus, the intradiscal area was washed out with 40 mg
of gentamicin, an appropriate prophylactic local antibiotic.
At the end of the procedure, the needle was pulled out and
a sterile bandage was applied as a dressing. No sutures
were used.
2.4. Postprocedural care
All patients were allowed unlimited walking, standing,
and sitting, and all were instructed to avoid heavy lifting,
forward skin bending, or crushing. After 10 to 14 days,
light work and home-based exercises with gentle flexions
and extensions were allowed.
All patients were evaluated using the Oswestry
Disability Index (ODI) and a VAS before treatment and at
1, 3, 6, and 12 months after treatment, and using the Patient
Satisfaction Scale at 12 months following treatment.
2.5. Statistical analysis
The data analysis was carried out using SPSS V 21.0
statistical software (IBM Corp., Armonk, NY, USA).
Descriptive data were expressed as mean ± standard
deviation (SD) for continuous variables and as number (n)
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and percentage (%) for nominal variables. The compatibility
of the variables to normal distribution was checked with
a Kolmogorov–Smirnov test. For abnormally distributed
variables, intragroup distribution was compared using
Friedman’s analysis of variance (ANOVA) test. If present,
multiple intertime comparisons of the differences were
evaluated using the Bonferroni adjusted Wilcoxon signedranks test. The power for nonparametric tests was unable
to be calculated [11]. Clinical significance was assessed
using Kendall’s W correlation coefficient for Friedman’s
ANOVA and a correlation coefficient for the Wilcoxon
signed-ranks test. Kendall’s W correlation coefficient
was interpreted using Cohen’s guidelines of 0.1 (small
effect), 0.3 (medium effect), and above 0.5 (strong effect).
The effect size of the Wilcoxon signed-ranks test was
interpreted according to Cohen’s criteria, and the values
of 0.2, 0.5, and 0.8 were considered small, medium, and
strong effect sizes, respectively. P < 0.05 was considered
statistically significant.
3. Results
A total of 29 patients were included in the study, and of
these, 14 were female and 15 were male, with a mean age
of 49.21 ± 6.82 years for women and 46.26 ± 7.18 years for
men. All patients were followed for 12 months in the pain
clinic.
GelStix implants were applied to 25 patients, to a
single level in L4–L5 in 16 patients, to L5–S1 in 9 patients,
and to 2 levels (L4–L5, L5–S1) in 4 patients. According
to the Patient Satisfaction Scale, which was evaluated at
12 months following the procedure, 4 patients rated the
procedure as very good, 21 as good, and 4 as moderate.
Overall, 86.2% of the patients rated the procedure as very
good or good (Table 1).

Table 1. Demographic data.
Sex

n

%

Male

15

51.7

Female

14

48.3

Level
L4–L5

16

55.17

L5–S1

9

31.04

L4–S1

4

13.79

Very good

4

13.8

Good

21

72.4

Moderate

4

13.8

PSS

PSS: Patient Satisfaction Score.
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The mean VAS scores were 7.14 ± 0.64 at baseline, 3.69
± 0.60 at 1 month, 2.93 ± 0.59 at 3 months, 2.62 ± 0.49 at 6
months, and 2.48 ± 0.63 at 12 months (Figure). Based on
the results of a Friedman test, the differences between the
VAS scores at baseline and at 1, 3, 6, and 12 months were
found to be statistically significant (P = 0.001) (Table 2).
Kendall’s W value for the VAS was calculated as
0.802, which is higher than 0.5, indicating a strong effect
size by Cohen’s criteria. This result was also clinically
significant [11,12]. When comparing binary months, all of
the differences between the VAS scores were statistically
significant (P < 0.05), while only the difference between
months 6 and 12 was not significant (P = 0.317). When
the effect size of binary comparisons for the VAS scores
was assessed according to Cohen’s criteria, the VAS scores
for months 6–12 were below mild clinical significance, 3–6
about mild, and 3–12 between mild and moderate clinical
significance, while the other time comparison results had
more than moderate clinical significance [13] (Table 2;
Figure).
The differences in the ODI scores of the patients
were found to be statistically significant (P = 0.001)
using a Friedman test. The mean ODI scores were 28.14
± 1.81 at baseline, 18.59 ± 1.84 at 1 month, 18.00 ± 1.10
at 3 months, 17.79 ± 1.01 at 6 months, and 17.35 ± 0.67
at 12 months. A decrease in the ODI scores in patients
with GelStix treatment was noted (Figure). Kendall’s W
value for the ODI scores was calculated at 0.635, which is
higher than 0.5, indicating a strong effect size by Cohen’s
criteria. This result was also clinically significant. When
comparing binary months, the differences between the
ODI scores were statistically significant (P < 0.05), except
for the differences between the 1st and 3rd months (P =
0.110) and the 3rd and 6th months (P = 0.295). When the
effect size of the binary comparisons of the ODI scores
was assessed according to Cohen’s criteria, the ODI scores
for months 3–6 had below mild clinical significance, 1–3
and 1–6 had about mild, and 3–12, 6–12, and 1–12 had
between mild and moderate clinical significance, while the
other time comparison results had more than moderate
clinical significance (Table 3).
4. Discussion
Disturbances of nutrient transport in degenerated discs
cause lactic acid formation and decreased pH levels [4].
Accumulations of lactic acid modify cellular activity by
downregulating PG synthesis, and it is the enzymes that
degrade the extracellular matrix that cause Gelstix to
stop the disk degeneration cycle. GelStix increases pH
in the disc: low pH is associated with degeneration and
inflammation, while increased pH causes the natural PGs
to swell and increase hydration. Adding liquid and volume
increases osmotic pressure, and low pH weakens the ability
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Figure. Comparison of the changes in VAS and ODI.
Table 2. The average of visual analogue score (VAS) results.
VAS score
(mean ± SD)
0

7.14 ± 0.64

1st month

3.69 ± 0.60

3rd month

2.93 ± 0.59

6th month

2.62 ± 0.49

12th month

2.48 ± 0.63

Test statistics*

Source of difference **
0–1, 0–3, 0–6, 0–12 (P < 0.001)
1–3, 1–6, 1–12 (P < 0.001)

χ2 = 93.078
P < 0.001

3–6 (P = 0.029), 3–12 (P = 0.002)
6–12 (P = 0.317)

*: Friedman variance analysis test statistical values.
**: Bonferroni adjusted Wilcoxon signed-ranks test statistical values.
Table 3. The average Oswestry Disability Index (ODI) scores.
ODI score
(mean ± SD)
0

28.14 ± 1.81

1st month

18.59 ± 1.84

3rd month

18.00 ± 1.10

6th month

17.79 ± 1.01

12th month

17.35 ± 0.67

Test statistics*

Source of difference **
0–1, 0–3, 0–6, 0–12 (P < 0.001)

χ2 = 93.078
P < 0.001

1–3 (P = 0.110), 1–6 (P = 0.038)
1–12 (P = 0.002), 3–6 (P = 0.295)
3–12 (P = 0.003), 6–12 (P = 0.012)

*: Friedman variance analysis test statistical values.
**: Bonferroni adjusted Wilcoxon signed-ranks test statistical values.

of PGs to bind to water; these factors lead to reduced
hydration within the disc and further deterioration of the
nutrient transport.
The ideal hydrogel must meet the following requirements
for NP renewal: i) it must be injectable, ii) it must prevent
the cells or gel from escaping after implantation, iii) it

must be strong and have adequate durability, iv) it must
have sufficient distension pressure with various loads, v) it
must support cell proliferation and matrix, and vi) it must
prevent adverse effects [14]. A hydrogel should support
cell growth and matrix, and should also have sufficient
mechanical strength for NP renewal.
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In our study of patients with DDD, we observed a
time-dependent decrease in the patients’ VAS and ODI
scores with GelStix treatment, and the changes before and
after the procedure indicated that the process contributed
significantly to the reduction in VAS and ODI scores. At 12
months, the mean VAS scores had decreased from 7.14 at
the beginning to 2.48 at the 12th month (P = 0.001), and
the mean ODI scores had decreased from 28.14 to 17.35
(P = 0.001).
Singh et al. [15] administered GelStix implantations for
22 patients with DDD in 2012 and found the VAS scores to
decrease from 8.5 to 3.0 (P < 0.0001) and the ODI scores to
decrease from to 25.1 to 10.2 (P < 0.0001) after the first 4
weeks of treatment. In our study, the VAS and ODI scores
of all patients with DDD at 12 months were similar to those
in the aforementioned studies, and none of the patients in
the study developed permanent neurological damage or
complications requiring additional surgery. Response to
treatment following GelStix implantation was noted early
on in the treatment according to the selection of suitable
patients and application by experienced operators.
In patients with no history of severe radiculopathy,
the rapid development of symptoms immediately after
implantation suggests a possible misplacement at the
annular ring [16]. In all patients, the cannula was carefully
drained after it was clarified as being located most centrally
in the nucleus pulposus via lateral and anteroposterior
views from the C-arm.
GelStix can grow rapidly by absorbing water and
can lead to an increase in radicular symptoms via root
compression or can cause a protruding disc to exert
pressure, resulting in direct radiculopathy. In 2 previous
case reports, the medical history of the 2 patients involved
revealed signs of disc compression and radiculopathy prior
to the procedure, and their symptoms intensified after 4
and 6 months. This finding suggests that both patients had
a broad-base protruding disc and a degenerated annulus
fibrosis defect before the procedure [9,17].
The first-line treatment of DDD is conservative [18],
and if conservative treatment fails, the current surgical
treatment options are to surgically immobilize the
degenerated disc segment, either with a fusion procedure
or with a mechanical arthroplasty device [19,20].

It was not possible to compare the outcomes of our
patients to results found in a systematic review of the
conservative treatments for DDD [21], as the DDD
patients were undergoing drug and physical therapy
for general back pain. In the treatment of chronic LBP,
multiple physical and rehabilitation interventions are
effective in the short-term but ineffective in the longterm [22], and intensive and long-term physical therapy
programs have been found to increase the severity of
pain in certain cases [23]. Nonsteroidal antiinflammatory
drugs (NSAIDs) and antidepressants with pain-relieving
effects of opioids have been reported as having less painrelieving effects in cases of chronic pain, and NSAIDs and
opioids in particular have been reported as having serious
side effects related to their long-term use [24].
4.1. Conclusions
The application of GelStix contributes to discal
restoration in discogenic back pain and mild radicular
pain, but it requires skilled practitioners as much as
the selection of suitable patients due to the potentially
serious complications. If the pain migrates towards the
epidural space in the case of a newly developed injury
or a preexisting weakness in the wall of the annular ring,
the risk of complications and the need for surgery may
increase due to severe radiculopathy. Based on the results
of the present study, it can be suggested that GelStix
intradiscal implant applications may be considered as
a long-term pain-relieving, effective, and functionally
beneficial treatment method for patients with DDD in
experienced centers when based on appropriate patient
selection.
4.2. Limitations
In terms of evaluating the long-term results of Gelstix
application after returning to routine daily life, the
patients’ smoking habits and alcohol intake, weight loss
or gain, occupational changes, and long-term quality of
sleeping could have been detected individually and stated
in the discussion. Thus, we could have had the chance
to analyze the reasons for VAS and ODI changes during
the control periods of 3 months. However, the data of the
patients in our study were only collected at the beginning
and specified follow-up times.
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